Recent studies have raised concerns about the reduced efficacy of clopidogrel when used concurrently with proton pump inhibitors because of competitive inhibition of the CYP2C19 isoenzyme. However, many of these studies had methodological limitations. We studied a cohort of 18 565 community-dwelling elderly patients discharged from hospital after percutaneous coronary intervention or acute coronary syndrome who were prescribed clopidogrel with or without a proton pump inhibitor. Our analysis did not demonstrate a large or statistically significant increase in the relative risk of myocardial infarction or death for patients treated concurrently with clopidogrel and proton pump inhibitors, but our data were consistent with the possibility of a modest clinical effect. Given the lack of compelling trial evidence documenting a meaningful gastroprotective effect from the coprescription of a proton pump inhibitor with clopidogrel, one prudent strategy would be to coprescribe proton pump inhibitors primarily in clopidogrel-treated patients at higher risk of adverse gastrointestinal events. See p 2322.
Angina Symptoms Are Associated With Mortality in Older Women With Ischemic Heart Disease
Angina symptoms have been reported to predict mortality in men, but the association between angina and subsequent mortality in older women is underinvestigated. Gender differences in the association between angina and mortality may be expected on the basis of gender differences in ischemic heart disease presentation and differences in age at onset. This study deals with mortality among 873 older women (77 to 83 years of age) participating in the Australian Longitudinal Study on Women's Health with self-reported ischemic heart disease. Over 4.5 years, 165 women (19%) died, and angina symptoms, assessed from Seattle Angina Questionnaire scores for physical limitation and angina frequency, were associated with mortality. Angina symptoms in women can by no means be discarded as a benign diagnosis. The Seattle Angina Questionnaire scores for physical limitation and angina frequency could provide a useful tool for risk assessment in older women. See p 2330.
Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease
Clopidogrel is metabolized in the cytochrome P450 pathway to its active metabolite, and smoking is an inducer of CYP1A2. Recent in vitro data suggest that smoking influences the platelet inhibitory effect of clopidogrel, yet the relationship between clopidogrel, smoking, and clinical outcomes is incompletely understood. The objectives of this study were 2-fold: First, to evaluate the relationship between smoking status (current, former, or never) and all-cause, cardiovascular, and cancer mortality in patients with established cardiovascular disease, and second, to investigate the safety and efficacy of clopidogrel versus placebo stratified by smoking status. Among patients with established cardiovascular disease, smoking status is a strong independent risk factor for all-cause mortality, cardiovascular mortality, cancer mortality, cardiovascular events, and bleeding risk. A significant interaction existed between current smokers and clopidogrel use for the outcomes of all-cause and cardiovascular mortality. Clopidogrel was most effective in reducing all-cause and cardiovascular mortality, while simultaneously increasing the risk of bleeding in current smokers, a finding not observed in former or never-smokers. The present analysis extends and reinforces evidence of the increase in total and cause-specific mortality caused by smoking, as well as the increase in bleeding in a population with established cardiovascular disease. The data suggest an important relationship between smoking status and the safety and efficacy of clopidogrel therapy. Further studies are needed to investigate this possibility. See p 2337.
Relations of Lipid Concentrations to Heart Failure Incidence: The Framingham Heart Study
Heart failure has increased in prevalence in recent decades. Dyslipidemia has been suspected of influencing heart failure risk, but few community-based epidemiological studies addressed this issue. Because the development of heart failure portends an increased burden of morbidity and mortality, it is important to understand the risk factors for this condition so that preventative strategies can be developed. In participants free of coronary heart disease at baseline, we evaluated prospectively the relations of high-density lipoprotein cholesterol (HDL-C) and non-HDL-C concentrations to heart failure incidence. We related both baseline and periodically updated lipid concentrations to heart failure incidence after adjustment for clinical covariates and interim occurrence of myocardial infarction. We observed a consistent positive relation of baseline and periodically updated non-HDL-C concentrations and an inverse relation of HDL-C concentrations to heart failure incidence. The relations of HDL-C and non-HDL-C to heart failure risk were statistically significant even after adjustment for interim myocardial infarction. heart failure occurrence. Our findings are consistent with the hypothesis that dyslipidemia increases heart failure risk independent of its association with myocardial infarction. Our data highlight a possible mechanism for the decrease in heart failure incidence noted in several trials of lipid-modification therapy and suggest that lipid modification may be a means of preventing heart failure. See p 2345.
Renal and Hepatic Function Improve in Advanced Heart Failure Patients During Continuous-Flow Support With the HeartMate II Left Ventricular Assist Device
The HeartMate II left ventricular assist device (LVAD) is a small continuous-flow device that has been shown to provide effective hemodynamic support and improve quality of life in patients being bridged to cardiac transplantation. However, because of the continuous flow of blood with this device, these patients often have no palpable pulse and a very low pulse pressure, and the subsequent effects of continuous flow on end-organ function are unclear. In patients who underwent placement of the HeartMate II as a bridge to transplantation and who were followed up for 6 months of support with the left ventricular assist device, we demonstrated that both hepatic and renal function in patients with abnormal baseline function improved to normal levels by month 1 to 2 and that they remained normal. Additionally, in patients with normal baseline function, we found that renal and hepatic function remained normal during continuous-flow support. In summary, despite low pulsatility, the HeartMate II continuous-flow left ventricular assist device improved both hepatic and renal function in advanced heart failure patients awaiting transplantation. See p 2352.
Prevention of Cardiac Dysfunction in Acute Coxsackievirus B3 Cardiomyopathy by Inducible Expression of a Soluble Coxsackievirus-Adenovirus Receptor
Group B coxsackieviruses (CVBs) are the prototypical agents of acute myocarditis in humans, but an effective targeted therapy is not yet available. Acute enteroviral myocarditis may not lead to initial mortality but often results in the insidious development of chronic dilated cardiomyopathy and terminal heart failure. Here, we analyze the therapeutic potential of a soluble (s) virus receptor molecule against CVB3 myocarditis, delivered by use of a gene therapy approach. We generated an inducible adenoviral vector (AdG12) for strictly drug (doxycycline)-dependent delivery of sCAR-Fc, a fusion protein composed of the coxsackievirus-adenovirus receptor (CAR) extracellular domain and the carboxyl terminus of human IgG1-Fc. After intravenous injection, AdG12 significantly improved systolic and diastolic function in CVB3-infected mice if sCAR-Fc expression was pharmacologically induced in a prophylactic or therapeutic setting. Importantly, the hemodynamics of animals treated with AdG12 were similar to those of healthy control animals. With respect to the underlying pathomechanism, sCAR-Fc completely blocked (prophylactic) or strongly reduced (therapeutic) cardiac CVB3 infection and the resultant myocardial injury and inflammation. The strength of the cardioprotective effect and the additional safety feature mediated by the strict drug dependency of the sCAR-Fc expression make this strategy a promising approach for treatment of this life-threatening cardiac disease. It may also serve as a paradigm for analogous treatments of other severe viral infections by systemic delivery of "virus-trap" proteins, generated either by vectors as described here or by direct intravenous infusion of the encoded recombinant protein. See p 2358.
Transcription Factor Fos-Related Antigen-2 Induces Progressive Peripheral Vasculopathy in Mice Closely Resembling Human Systemic Sclerosis
Microvascular alterations are one of the earliest phenomena in the pathophysiology of systemic sclerosis. However, the molecular mechanisms initiating and perpetuating the peripheral vasculopathy are unknown. In this study, we show that Fra-2 transgenic mice display various features of the peripheral vasculopathy of human systemic sclerosis with a reduction in capillaries and early apoptosis of endothelial cells. Furthermore, this animal model combines clinically evident peripheral and pulmonary vasculopathy with fibrosis of the skin and internal organs, particularly the lungs. We could also demonstrate that apoptosis of endothelial cells occurs before the manifestation of fibrosis and contributes to the reduction in capillary density in later stages of the model as supposed for human systemic sclerosis. Therefore, Fra-2 transgenic mice can be proposed as an excellent preclinical model that allows us to study the link between vasculopathy and fibrosis. This model also enables the testing of antifibrotic agents and drugs targeting vasculopathy simultaneously. Because we provide evidence that Fra-2 is present in human systemic sclerosis, Fra-2 might also represent a promising future target to treat both vasculopathy and fibrosis in systemic sclerosis patients. See p 2367.
Reciprocal Regulation of MicroRNA-1 and Insulin-Like Growth Factor-1 Signal Transduction Cascade in Cardiac and Skeletal Muscle in Physiological and Pathological Conditions
MicroRNAs (miRNAs/miRs) are small conserved RNA molecules of 22 nucleotides that negatively modulate gene expression primarily through base paring to the 3Ј untranslated region of target messenger RNAs. The muscle-specific miR-1 has been implicated in cardiac hypertrophy, heart development, cardiac stem cell differentiation, and arrhythmias through targeting of regulatory proteins. In this study, we investigated the molecular mechanisms through which miR-1 intervenes in regulation of cardiac and skeletal muscle cell growth and differentiation. We demonstrate that miR-1 controls the expression of insulin-like growth factor-1 (IGF-1) and IGF-1 receptor protein levels by translation. The IGF-1 pathway is critically involved in many aspects of cardiac development and cardiac function. We found that in conditions in which miR-1 is decreased, such as cardiac hypertrophy, IGF-1 is increased; the regulation is reciprocal because IGF-1 stimulation leads to downregulation of miR-1 levels. This effect is dependent on IGF-1 inhibition of the Foxo3 transcription factor, which regulates miR-1 promoter activity. The clinical relevance of these observations is demonstrated by analyzing the expression of miR-1 in cardiac biopsies of patients with acromegaly, a condition in which growth hormone and IGF-1 are overproduced and cardiac myocyte size is dramatically increased; miR-1 levels inversely correlate with echocardiographic parameters of cardiac mass in these patients. Our results add information in regard to the manner in which the IGF-1 pathway regulates cardiac function, demonstrating the role of miR-1 in response to cardiac stress and hypertrophy. See p 2377.
Persistent Diastolic Dysfunction Late After Valve Replacement in Severe Aortic Regurgitation
Patients with severe aortic regurgitation show eccentric left ventricular hypertrophy and structural changes of the myocardium. Reversibility of functional and structural changes after successful valve replacement may be limited. Persistent diastolic dysfunction was
